Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
JM-010 by Contera Pharma for Dyskinesia: Likelihood of Approval
JM-010 is under clinical development by Contera Pharma and currently in Phase II for Dyskinesia. According to GlobalData, Phase II...